The Cancer
diagnostics testing includes tests and processes that authorizes the
existence of diseases and identify the proper tumor variety, position, extent
and stage which will support the physician to give the appropriate treatment.
The biopsy, tumor biomarker tests, nuclear medicine scans are the some of the
diagnostics tests utilized for the cancer diagnostics. According to the prediction
of the National cancer institute, in US approximately 1.6 million fresh cases
of cancer are detected, and 594,690 people have deceased owing to the cancer in
2016.
Additionally, the market of cancer diagnostics is boosting
owing to growing incidence of cancer across the globe, increasing elderly
populace around the world, augmented usage of customized medicine in the
clinical practice, and advancements of new novel technologies namely
nanotechnology. Whereas, the China economy has observed 4.3 million new cases
of cancer and 2.8 million deaths in 2015. Whereas, according to the Indian
council for medical research, India registers for 1.4 million new cases of
cancer and 736,000 cancers correlated death in 2016.
Furthermore, the large enterprises in the cancer
diagnostics market are significantly elaborating the techniques of delivering
the services and innovating new technologies for delivering the better consumer
satisfaction. According to the report analysis, ‘Global
Cancer Diagnostics market and Drivers, Restraints, and Opportunities 2018-2024’
states that there are numerous key players which recently performing in the
cancer diagnostics market more positively for leading the fastest market growth
and registering the high value of market share across the globe while
investigating the new techniques of treating the victims and spreading the
awareness related to the personalized medicines includes F. Hoffmann-La Roche
Ltd, Abbott Laboratories, Inc., Siemens Healthineers (Siemens AG), Thermo
Fisher Scientific, Inc., GE Healthcare, Qiagen N.V., Agilent Technologies,
Inc., Hologic, Inc., Koninklijke Philips N. V. and several other predominate
& niche players.
The Global Cancer Diagnostics Market is predicted to observe
a handsome amount of CAGR of 11.6% during the forecast period of 2018-2024.
Whereas, based on the region, the market of cancer diagnostics is segmented
into North America, Europe, Asia Pacific, and Rest of the World (RoW). The
North America is set to be the important region for the cancer diagnostics
market growth followed by Europe, Asia Pacific and Rest of the World.
Furthermore, based on the applications, the global cancer diagnostics market by
application is sectored into lung cancer, breast cancer, colorectal cancer,
prostate cancer and others. For instance, the Lung cancer occupied the principal
share in 2017, and breast cancer application is anticipated to be fastest increasing
segment during the reviewed period.
Not only has this, on the basis of end-users, the
global cancer diagnostics market by end-users is fragmented into Hospitals,
diagnostic laboratories, academic & research institutes and several others.
Hospitals conquer a major share of cancer diagnostics market in 2017 and are anticipated
to be the identical for next five years. Therefore, in the near years, it is
anticipated that the market of Cancer Diagnostics will increase around the globe
more positively over the forecasted period.
For more
information on the research report, refer to below link:-
Related Report:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
